Complex consisted of a polysaccharide and an HBP
    1.
    发明申请
    Complex consisted of a polysaccharide and an HBP 有权
    复合物由多糖和HBP组成

    公开(公告)号:US20100184965A1

    公开(公告)日:2010-07-22

    申请号:US12585886

    申请日:2009-09-28

    摘要: The invention relates to a complex consisted of a polysaccharide and an HBP, said polysaccharide being consisted from glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative. The invention also relates to a pharmaceutical composition comprising a complex according to the invention and to the use of a polysaccharide consisted of glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative, for the preparation of a pharmaceutical formulation of stable HBPs.

    摘要翻译: 本发明涉及由多糖和HBP组成的复合物,所述多糖由(1,6)和/或(1,4)和/或(1,3)和/或(1,2)的糖苷键组成 )类型并用至少一种可成盐或盐化的色氨酸衍生物官能化。 本发明还涉及包含根据本发明的复合物和由(1,6)和/或(1,4)和/或(1,3)和/或(1,3)的糖苷键组成的多糖和/ 或(1,2)型,并用至少一种可成盐或盐化的色氨酸衍生物官能化,用于制备稳定HBP的药物制剂。

    Complex consisted of a polysaccharide and an HBP
    3.
    发明授权
    Complex consisted of a polysaccharide and an HBP 有权
    复合物由多糖和HBP组成

    公开(公告)号:US08367640B2

    公开(公告)日:2013-02-05

    申请号:US12585886

    申请日:2009-09-28

    摘要: The invention relates to a complex consisted of a polysaccharide and an HBP, said polysaccharide being consisted from glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative. The invention also relates to a pharmaceutical composition comprising a complex according to the invention and to the use of a polysaccharide consisted of glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative, for the preparation of a pharmaceutical formulation of stable HBPs.

    摘要翻译: 本发明涉及由多糖和HBP组成的复合物,所述多糖由(1,6)和/或(1,4)和/或(1,3)和/或(1,2)的糖苷键组成 )类型并用至少一种可成盐或盐化的色氨酸衍生物官能化。 本发明还涉及包含根据本发明的复合物和由(1,6)和/或(1,4)和/或(1,3)和/或(1,3)的糖苷键组成的多糖和/ 或(1,2)型,并用至少一种可成盐或盐化的色氨酸衍生物官能化,用于制备稳定HBP的药物制剂。

    DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS
    4.
    发明申请
    DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS 审中-公开
    由疏水性氨基酸功能化的地西泮

    公开(公告)号:US20120041079A1

    公开(公告)日:2012-02-16

    申请号:US13250803

    申请日:2011-09-30

    摘要: Dextran of the following general formula I: is described, wherein R represents a chain containing from 1 to 15 carbon atoms and having at least one acid functional group prior to attachment to AA, the chain optionally being branched and/or unsaturated and containing one or more heteroatoms, such as O, N or/and S, F represents an ester, a carbamate or an ether, AA represents a hydrophobic amino acid radical, L or D, derived from a coupling between an amine of an amino acid and at least one acid functional group of R; the amino acid, prior to attachment to R, being selected from the group consisting of tryptophan, phenylalanine, leucine, isoleucine, alanine and valine, and alcohol, amide or decarboxylated derivatives thereof, and alkaline cation salts thereof, i represents the molar fraction of substituent F—R-[AA]n per glycosidic unit and is from 0.1 to 2, n represents the molar fraction of R groups substituted by AA and is from 0.05 to 1, and wherein for R groups not substituted by AA, the acid(s) of the group R are alkaline cation carboxylates such as Na or K.

    摘要翻译: 描述了以下通式I的葡聚糖,其中R表示含有1至15个碳原子并且在与AA连接之前具有至少一个酸官能团的链,该链任选是支链和/或不饱和的,并且含有一个或 更多的杂原子,例如O,N或/和S,F代表酯,氨基甲酸酯或醚,AA代表疏水性氨基酸基团,L或D衍生自氨基酸的胺与至少 一个酸官能团的R; 氨基酸在与R连接之前选自色氨酸,苯丙氨酸,亮氨酸,异亮氨酸,丙氨酸和缬氨酸,以及其醇,酰胺或其脱羧基衍生物及其碱性阳离子盐,i表示 取代基F-R- [AA] n,为0.1〜2,n表示被AA取代的R基的摩尔分数,为0.05〜1,对于不被AA取代的R基,酸( 的基团R是碱性阳离子羧酸盐,例如Na或K.

    Angiogenic composition
    8.
    发明申请
    Angiogenic composition 审中-公开
    血管生成成分

    公开(公告)号:US20080293635A1

    公开(公告)日:2008-11-27

    申请号:US12078443

    申请日:2008-03-31

    IPC分类号: A61K38/16 A61P9/00

    摘要: The present invention relates to a amphiphilic polymer in the preparation of a therapeutic composition for promoting angiogenesis at its site of administration, comprising a complex between a polymer and a PDGF, wherein the polymer is amphiphilic.In an embodiment, the PDGF is selected from the group of the PDGFs (platelet-derived growth factors) and the amphiphilic polymer is selected from the group: The invention relates also to the therapeutic composition is in the form of a gel, a cream, a solution, a spray, a paste or a patch or a dressing.

    摘要翻译: 本发明涉及制备用于在其施用部位促进血管发生的治疗组合物的两亲性聚合物,其包含聚合物和PDGF之间的复合物,其中所述聚合物是两亲性的。 在一个实施方案中,PDGF选自PDGF(血小板衍生生长因子)组,两亲性聚合物选自:本发明还涉及治疗组合物,其形式为凝胶,霜剂, 溶液,喷雾剂,糊剂或贴剂或敷料。

    Administration form of osteogenic protein complexes

    公开(公告)号:US08497253B2

    公开(公告)日:2013-07-30

    申请号:US12591442

    申请日:2009-11-19

    IPC分类号: A61K31/721 C08B37/02

    摘要: Osteogenic compositions composed of a coprecipitate that contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide, the coprecipitate being in divided form, are described. Kits are also described, as are a process for preparing the coprecipitate in divided form, containing at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide.